Prostate Cancer - Results from #620

Validation of candidate protein biomarkers previously identified by genetic instruments for prostate cancer risk: A prospective cohort analysis of directly measured protein levels in the ARIC study. August 19, 2024

Contemporary treatment standards and trends of systemic therapy in metastatic hormone-sensitive prostate cancer-implementing study data in clinical practice. August 16, 2024

Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer. August 16, 2024

Evaluating the Efficacy of ChatGPT as a Patient Education Tool in Prostate Cancer: Multimetric Assessment. August 16, 2024

Standardized template for clinical reporting of PSMA PET/CT scans. August 16, 2024

Pain and Health-related Quality of Life with Biweekly Versus Triweekly Cabazitaxel Schedule in Older Men with Metastatic Castration-resistant Prostate Cancer in the Multicenter, Randomized CABASTY Trial. August 16, 2024

Preoperative Prostate Magnetic Resonance Imaging-based Anatomical Predictors of Early Urinary Continence Following Single-port Transvesical Robot-assisted Radical Prostatectomy. August 16, 2024

NICE Recommends ORGOVYX® (Relugolix) as the First Oral ADT Treatment for Hormone Sensitive Prostate Cancer in England August 15, 2024

Impact of the diagnostic label for a low-risk prostate lesion: protocol for two online factorial randomised experiments. August 15, 2024

Abiraterone Acetate Versus Enzalutamide Against Chemo-Naïve Castration-Resistant Prostate Cancer With Full-Dose Induction. August 15, 2024

Burden of 30 cancers among men: Global statistics in 2022 and projections for 2050 using population-based estimates August 14, 2024

Technical and Ethical Considerations in Telesurgery August 14, 2024

A contemporary review: mpMRI in prostate cancer screening and diagnosis. August 14, 2024

Select black men are potential candidates for prostate hemi-ablation based on radical prostatectomy histopathology for intermediate-risk prostate cancer-a multicenter SEARCH cohort study. August 14, 2024

Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study. August 14, 2024

A Scaled Proteomic Discovery Study for Prostate Cancer Diagnostic Markers Using ProteographTM and Trapped Ion Mobility Mass Spectrometry. August 14, 2024

Randomized Trial of Transverse vs Vertical Extraction Site Incision After Robotic Radical Prostatectomy. August 14, 2024

Impact of Posttreatment SPECT/CT on Patient Management During 177Lu-PSMA-617 Radiopharmaceutical Therapy. August 14, 2024

Primary Care Use and 90-Day Mortality Among Older Adults Undergoing Cancer Surgery. August 14, 2024

Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma. August 14, 2024

Page 32 of 1447